Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1- yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands

European Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2010, Pages 5878-5886

  Silvestri, Romano ^a   Ligresti, Alessia ^b   La Regina, Giuseppe ^a   Piscitelli, Francesco ^a   Gatti, Valerio ^a   Lavecchia, Antonio ^c   Brizzi, Antonella ^d   Pasquini, Serena ^d   Allar, Marco ^b   Fantini, Noemi ^b   Carai, Mauro Antonio Maria ^b   Bigogno, Chiara ^e   Rozio, Marco Giulio ^e   Sinisi, Roberta ^e   Novellino, Ettore ^c   Colombo, Giancarlo ^b   Di Marzo, Vincenzo ^b   Dondio, Giulio ^e   Corelli, Federico ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e NiKem Research   (Italy)

Author keywords

Cannabinoid; Human recombinant CB receptor type 1; Pharmacological studies; Pyrrole bioisoteres; Structure activity relationships

Indexed keywords

1 (2,4 DICHLOROPHENYL) 4 METHYL N (OCTAN 2 YL) 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 4 METHYL N PROPYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 4 METHYL N TERT PENTYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) 4 METHYL N PENTYL 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) 4 METHYL N TERT PENTYL 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) N (3,3 DIMETHYLBUTYL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) N (5 HYDROXYPENTYL) 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) N HEPTYL 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) N HEXYL 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) N ISOPROPYL 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) N (3,3 DIMETHYLBUTYL) 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) N (5 HYDROXYPENTYL) 4 METHYL N PROPYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) N HEPTYL 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) N HEXYL 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) N ISOPROPYL 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DIFLUOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) N HEPTYL 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; 3 CARBOXAMIDE NITROGEN; ALKYL GROUP; AMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; N ALKYL 1 ARYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE DERIVATIVE; N BUTYL 1 (2,4 DICHLOROPHENYL) 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; N BUTYL 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; N TERT BUTYL 1 (2,4 DICHLOROPHENYL) 4 METHYL 5 (1H PYRROL 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; N TERT BUTYL 1 (2,4 DICHLOROPHENYL) 5 (2,5 DIMETHYL 1H PYRROL 1 YL) 4 METHYL 1H PYRAZOLE 3 CARBOXAMIDE; NITROGEN; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD INTAKE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMIDES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; HUMANS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649319952     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.09.053     Document Type: Article

References (42)

1. J.R. Sowers Obesity as a cardiovascular risk factor Am. J. Med. 115 2003 37S 41S
2. W.Y. Leung, T.G. Neil, J.C. Chan, and B. Tomlinson Weight management and current options in pharmacotherapy: orlistat and sibutramine Clin. Therapeut. 25 2003 58 80
3. European Medicines Agency recently decided to withdraw sibutramine due to cardiovasclar risks.
4. J. Lee, K.-S. Song, J. Kang, S.H. Lee, and J. Lee New trends in medicinal chemistry approaches to antiobesity therapy Curr. Top. Med. Chem. 9 2009 564 596
5. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7 2008 438 455
6. S. Pavlopoulos, G.A. Thakur, S.P. Nikas, and A. Makriyannis Cannabinoid receptors as therapeutic targets Curr. Pharm. Des 12 2006 1751 1769
7. L. Bellocchio, G. Mancini, V. Vicennati, R. Pasquali, and U. Pagotto Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases Curr. Opin. Pharm. 6 2006 586 591
8. D.M. Lambert, and C.J. Fowler The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications J. Med. Chem. 48 2005 5059 5087
9. R.S. Padwal, and S.R. Majumdar Drug treatments for obesity: orlistat, sibutramine, and rimonabant Lancet 369 2007 71 77
10. S.A. Doggrell Is rimonabant efficacious and safe in the treatment of obesity? Expert Opin. Pharmacother. 9 2008 2727 2731
11. D.R. Janero, and A. Makriyannis Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Drug Disc. 14 2009 43 65
12. H.J. Seo, M.J. Kim, S.H. Lee, S.-H. Lee, M.E. Jung, M.-S. Kim, K. Ahn, J. Kim, and J. Lee Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand Bioorg. Med. Chem. 18 2010 1149 1162
13. M. Cooper, J.-M. Receveur, E. Bjurling, P.K. Nørregaard, P.A. Nielsen, N. Sköld, and T. Högberg Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists Bioorg. Med. Chem. Lett. 20 2010 26 30
14. J. Boström, R.I. Olsson, J. Tholander, P.J. Greasley, E. Ryberg, H. Nordberg, S. Hjorth, and L. Cheng Novel thioamide derivatives as neutral CB1 receptor antagonists Bioorg. Med. Chem. Lett. 20 2010 479 482
15. J.S. Debenham, C.B. Madsen-Duggan, R.B. Toupence, T.F. Walsh, J. Wang, X. Tong, S. Kumar, J. Lao, T.M. Fong, J.C. Xiao, C.R.-R.C. Huang, C.-P. Shen, Y. Feng, D.J. Marsh, D.S. Stribling, L.P. Shearman, A.M. Strack, and M.T. Goulet Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1 Bioorg. Med. Chem. Lett. 20 2010 1448 1452
16. J.H.M. Lange, H.K.A.C. Coolen, M.A.W. van der Neut, A.J.M. Borst, B. Stork, P.C. Verveer, and C.G. Kruse Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism J. Med. Chem. 53 2010 1338 1346
17. H. Pettersson, A. Bülow, F. Ek, J. Jensen, L.K. Ottesen, A. Fejzic, J.-N. Ma, A.L. Del Tredici, E.A. Currier, L.R. Gardell, A. Tabatabaei, D. Craig, K. McFarland, T.R. Ott, F. Piu, E.S. Burstein, and R. Olsson Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists J. Med. Chem. 52 2009 1975 1982
18. P. Diaz, S.S. Phatak, J. Xu, F. Astruc-Diaz, C.N. Cavasotto, and M. Naguib 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction J. Med. Chem. 52 2009 433 444
19. G. Szabó, B. Varga, D. Páyer-Lengyel, A. Szemzó, P. Erdélyi, K. Vukics, J. Szikra, E. Hegyi, M. Vastag, B. Kiss, J. Laszy, I. Gyertyán, and J. Fischer Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists J. Med. Chem. 52 2009 4329 4337
20. Representative bioisosteres of 1 are depicted in our previous paper (see Ref. [9]).
21. D.A. Griffith, J.R. Hadcock, S.C. Black, P.A. Iredale, P.A. Carpino, P. Da Silva-Jardine, R. Day, J. DiBrino, R.L. Dow, M.S. Landis, R.E. O'Connor, and D.O. Scott Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]- 4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist J. Med. Chem. 52 2009 234 237
22. R.L. Dow, P.A. Carpino, J.R. Hadcock, S.C. Black, P.A. Iredale, P. Da Silva-Jardine, S.R. Schneider, E.S. Paight, D.A. Griffith, D.O. Scott, R.E. O'Connor, and C.I. Nduaka Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7- (2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity J. Med. Chem. 52 2009 2652 2655
23. J.S. Debenham, C.B. Madsen-Duggan, J. Wang, X. Tong, J. Lao, T.M. Fong, M.-T. Schaeffer, J.C. Xiao, C.C.R.-R. Huang, C.-P. Shen, D.S. Stribling, L.P. Shearman, A.M. Strack, D.E. MacIntyre, J.J. Hale, and T.F. Walsh Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation Bioorg. Med. Chem. Lett. 19 2009 2591 2594
24. R. Smith, A.Z. Fathi, S.-E. Brown, S. Choi, J. Fan, S. Jenkins, H.C.E. Kluender, A. Konkar, R. Lavoie, R. Mays, J. Natoli, S.J. O'Connor, A.A. Ortiz, B. Podlogar, C. Taing, S. Tomlinson, T. Tritto, and Z. Zhang Constrained analogs of CB1 antagonists: 1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives Bioorg. Med. Chem. Lett. 17 2007 673 678
25. R. Silvestri, M.G. Cascio, G. La Regina, F. Piscitelli, A. Lavecchia, A. Brizzi, S. Pasquini, M. Botta, E. Novellino, V. Di Marzo, and F. Corelli Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides J. Med. Chem. 51 2008 1560 1576
26. R. Silvestri, A. Ligresti, G. La Regina, F. Piscitelli, A. Lavecchia, A. Brizzi, S. Pasquini, M. Allar, N. Fantini, M.A.M. Carai, E. Novellino, G. Colombo, V. Di Marzo, and F. Corelli Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile Bioorg. Med. Chem. 17 2009 5549 5564
27. A. Brizzi, V. Brizzi, M.G. Cascio, T. Bisogno, R. Siriani, and V. Di Marzo Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors J. Med. Chem. 48 2005 7343 7350
28. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
29. D. Hurst, U. Umejiego, D. Lynch, H. Seltzman, S. Hyatt, M. Roche, S. McAllister, D. Fleischer, A. Kapur, M. Abood, S. Shi, J. Jones, D. Lewis, and P. Reggio Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction J. Med. Chem. 49 2006 5969 5987
30. D.P. Hurst, D.L. Lynch, J. Barnett-Norris, S.M. Hyatt, H.H. Seltzman, M. Zhong, Z.H. Song, J. Nie, D. Lewis, and P.H. Reggio N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor Mol. Pharmacol. 62 2002 1274 1287
31. S.D. McAllister, G. Rizvi, S. Anavi-Goffer, D.P. Hurst, J. Barnett-Norris, D.L. Lynch, P.H. Reggio, and M.E. Abood An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region J. Med. Chem. 46 2003 5139 5152
32. G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, and G.L. Gessa Appetite suppression and weight loss after the cannabinoid antagonist SR 141716 Life Sci. 63 1998 PL113 117
33. V. Di Marzo, S.K. Goparaju, L. Wang, J. Liu, S. Bátkai, Z. Járai, F. Fezza, G.I. Miura, R.D. Palmiter, T. Sugiura, and G. Kunos Leptin-regulated endocannabinoids are involved in maintaining food intake Nature 410 2001 822 825
34. Molecular Operating Environment (MOE), Version 2005.06 2005 Chemical Computing Group, Inc Montreal, Canada
35. C.C. Huang, G.S. Couch, E.F. Pettersen, and T.E. Ferrin Chimera: an extensible molecular modelling application constructed using standard components Pac. Symp. Biocomput. 1 1996 724
36. D.A. Case, T.A. Darden, T.E. Cheatham III, C.L. Simmerling, J. Wang, R.E. Duke, R. Luo, K.M. Merz, D.A. Pearlman, M. Crowley, R.C. Walker, W. Zhang, B. Wang, S. Hayik, A. Roitberg, G. Seabra, K.F. Wong, F. Paesani, X. Wu, S. Brozell, V. Tsui, H. Gohlke, L. Yang, C. Tan, J. Mongan, V. Hornak, G. Cui, P. Beroza, D.H. Mathews, C. Schafmeister, W.S. Ross, and P.A. Kollman AMBER 9 2006 University of California San Francisco
37. W.D. Cornell, P. Cieplak, C.I. Bayly, I.R. Gould, K.M. Merz Jr., D.M. Ferguson, D.C. Spellmeyer, T. Fox, J.W. Caldwell, and P.A. Kollman A second generation force field for the simulation of proteins, nucleic acids, and organic molecules J. Am. Chem. Soc. 117 1995 5179 5197
38. J.A. Ballesteros, and H. Weinstein Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors Methods Neurosc. 25 1995 366 428
39. A.M. van Rhee, and K.A. Jacobson Molecular architecture of G-protein-coupled receptors Drug Dev. Res. 37 1996 1 38
40. K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, B.A. Fox, I.L. Trong, D.C. Teller, T. Okada, R.E. Stenkamp, M. Yamamoto, and M. Miyano Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 2000 739 745
41. GOLD, Version 4.0 2008 CCDC Software Limited Cambridge, U.K
42. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748